Larimar Therapeutics, Inc. (LRMR)

Larimar Therapeutics, Inc. (LRMR) — VMCI valuation read

Across 120 indicators, Larimar Therapeutics, Inc. (LRMR) lands at VMCI 33/100. The Healthcare sector median is 50, so the 18-point below-median read is the active comparison. Pillar weighting on the score: Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%.

No material Form 4 disclosures landed on LRMR in the past 30 days. Quiet insider tape removes one signal source; the active reads stay with the trailing-twelve-month financials and the next 10-Q.

**Investor frame.** On Value, LRMR trades at 19.0x earnings, 6% above the Healthcare median of 18.0x; the EV/EBITDA delta of -2.0x reinforces that single line. On Quality, ROIC of 9.0% trails the Healthcare median (10.0%) by 1.0pp. On Risk, net debt to EBITDA of -1.6x leaves covenant headroom for LRMR on the trailing balance sheet.

LRMR fell 2.0% over the trailing 7 days, with a -4.0% read on a 30-day basis.